influenza
viru
iav
caus
season
epidem
respiratori
ill
caus
mild
sever
ill
potenti
death
antivir
drug
import
countermeasur
iav
howev
drug
resist
develop
thu
new
therapeut
approach
sought
previous
demonstr
antivir
activ
novel
nuclear
export
inhibitor
drug
verdinexor
reduc
influenza
replic
vitro
pulmonari
viru
burden
mice
studi
vivo
efficaci
verdinexor
evalu
two
anim
model
influenza
viru
infect
mice
ferret
mice
verdinexor
efficaci
limit
viru
shed
reduc
pulmonari
proinflammatori
cytokin
express
moder
leukocyt
infiltr
bronchoalveolar
space
similarli
verdinexortr
ferret
reduc
lung
patholog
viru
burden
inflammatori
cytokin
express
nasal
wash
exud
find
support
antivir
efficaci
verdinexor
warrant
develop
novel
antivir
therapeut
influenza
infect
influenza
virus
iav
emerg
virus
caus
season
epidem
period
pandem
annual
epidem
caus
iav
substanti
caus
hospit
death
unit
state
year
worldwid
caus
million
new
case
diseas
children
year
age
despit
substanti
research
mechan
action
modest
progress
made
develop
iav
drug
annual
influenza
vaccin
avail
antigen
drift
antigen
shift
emerg
virus
natur
reduc
vaccin
efficaci
control
current
approv
antiinfluenza
viru
drug
inhibitor
amantadin
rimantadin
na
inhibitor
oseltamivir
zanamivir
peramivir
drugresist
channel
inhibitor
associ
singl
multipl
amino
acid
substitut
transmembran
region
transmiss
inhibitor
resist
influenza
viru
strain
carri
mutat
class
approv
antivir
drug
effect
administ
within
h
symptom
onset
narrow
therapeut
valu
similarli
number
mutat
na
virus
demonstr
select
presenc
na
inhibitor
vitro
thu
new
antivir
activ
sought
host
cellular
gene
requir
viru
replic
appeal
antivir
target
due
limit
develop
resistancemut
alreadi
small
molecular
drug
identifi
target
host
gene
current
preclin
clinic
investig
potenti
repurpos
karyopharm
therapeut
recent
develop
firstinclass
novel
select
inhibitor
nuclear
export
sine
compound
use
molecular
model
screen
small
virtual
librari
compound
ne
groov
human
compound
inhibit
nuclearcytoplasm
export
revers
bind
cargo
recognit
site
oral
bioavail
sine
compound
origin
develop
therapeut
variou
hematolog
malign
drug
forc
nuclear
retent
accumul
function
activ
tumor
suppressor
protein
limit
oncogenesi
one
sine
compound
verdinexor
complet
registrationdirect
studi
companion
dog
newli
diagnos
first
relaps
nonhodgkin
lymphoma
nhl
fda
center
veterinari
medicin
cvm
consid
effect
safeti
technic
section
minor
use
minor
speci
mum
design
complet
support
condit
approv
oral
verdinexor
singl
agent
treatment
lymphoma
companion
dog
new
anim
drug
applic
nada
addit
verdinexor
recent
found
effect
inhibit
replic
variou
influenza
b
viru
strain
block
nuclear
export
viral
ribonucleoprotein
complex
preliminari
vivo
studi
demonstr
verdinexor
efficaci
limit
viru
burden
inflammatori
cytokin
express
lung
mice
infect
mouseadapt
strain
pandem
influenza
viru
mice
receiv
oral
verdinexor
treatment
also
display
reduc
lung
patholog
mortal
upon
lethal
viru
infect
madindarbi
canin
kidney
mdck
cell
atcc
cell
atcc
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
heat
inactiv
fb
hyclon
incub
co
parent
mouseadapt
influenza
propag
previous
describ
mgkg
oseltamivir
twice
daili
infect
preliminari
studi
conduct
determin
efficaci
treatment
regimen
verdinexor
result
show
mgkg
day
efficaci
yet
well
toler
data
shown
day
pi
mice
sacrif
bal
fluid
collect
determin
amount
viru
proinflammatori
cytokin
secret
describ
determin
efficaci
verdinexoroseltamivir
combin
treatment
mice
treat
oral
mgkg
verdinexor
day
pi
combin
mgkg
oseltamivir
twice
daili
day
day
mice
euthan
lung
collect
viru
titrat
determin
efficaci
late
dose
verdinexor
mice
infect
mouseadapt
treat
mgkg
verdinexor
day
day
day
day
mgkg
oseltamivir
twice
daili
day
pi
lung
harvest
day
pi
viru
titrat
surviv
studi
mice
infect
lethal
dose
mouseadapt
intranas
treat
mgkg
verdinexor
day
mgkg
oseltamivir
twice
daili
day
start
day
pi
mice
evalu
weight
clinic
sign
surviv
day
pharmacokinet
pk
studi
oral
verdinexor
treatment
n
male
mice
per
time
point
g
weight
bk
laboratori
anim
co
ltd
shanghai
china
qualif
scxk
sh
use
plasma
verdinexor
concentr
determin
ultrahighperform
liquid
chromatographymass
spectrometri
method
previous
describ
evalu
amount
viru
shed
bal
supernat
serial
dilut
titer
mdck
cell
h
evalu
viru
titer
lung
perform
previous
describ
hemagglutin
ha
assay
perform
use
turkey
rbc
viru
titer
calcul
tissu
cultur
infecti
dose
tcid
use
spearmankarb
formula
level
cytokin
chemokin
bal
analyz
use
milliplex
map
mous
cytokinechemokin
magnet
bead
panel
emd
millipor
luminex
system
character
inflammatori
cell
infiltr
bal
cell
resuspend
pb
count
evalu
flow
cytometri
briefli
cell
incub
fc
block
apc
antimous
antimous
pe
antimous
cell
antimous
bd
pharmingen
stain
buffer
bsa
pb
min
cell
wash
stain
buffer
fix
formaldehyd
sampl
run
lsrii
flow
cytomet
bd
bioscienc
analyz
use
flowjo
tree
star
young
adult
male
ferret
tripl
f
farm
weigh
n
per
treatment
group
use
studi
nasal
wash
collect
ferret
establish
basal
cytokin
express
profil
cell
collect
nasal
wash
concentr
centrifug
subject
rna
isol
ferret
cytokin
qrtpcr
describ
ferret
inocul
ml
infecti
dose
ferret
treat
oral
mgkg
verdinexor
daili
qd
mgkg
verdinexor
mgkg
oseltamivir
twice
daili
bid
day
start
h
preinfect
ferret
monitor
clinic
symptom
bodi
temperatur
activ
respiratori
sign
weight
loss
daili
day
pi
nasal
wash
collect
centrifug
cell
count
use
determin
cytokin
gene
express
day
pi
ferret
sacrif
lung
collect
histopatholog
analys
section
left
cranial
lung
lobe
homogen
use
determin
lung
viru
titer
describ
pk
analysi
plasma
verdinexor
concentr
determin
n
male
ferret
total
rna
isol
nasal
wash
cell
use
rneasi
mini
kit
qiagen
cdna
synthes
use
verso
cdna
synthesi
kit
random
hexam
primer
thermo
scientif
quantit
pcr
perform
use
ferret
gapdh
gene
specif
primer
rt
sybr
green
qpcr
master
mix
sabiosci
thermocycl
previous
describ
ct
valu
cytokin
normal
gapdh
express
rel
basal
sampl
calcul
use
formula
left
cranial
lung
lobe
remov
viru
titrat
remain
lung
inflat
buffer
formalin
immers
formalin
follow
fixat
lung
lobe
embed
paraffin
four
micron
section
stain
hematoxylin
eosin
previous
describ
overal
lung
patholog
score
rang
unremark
minim
chang
bronchiolar
epithelium
minim
perivascular
inflamm
mild
multifoc
bronchial
andor
bronchiolar
epitheli
chang
perivascular
peribronchialbronchiolar
inflamm
moder
multifoc
bronchial
andor
bronchiolar
epitheli
chang
perivascular
peribronchialbronchiolar
alveolar
inflamm
mark
diffus
bronchial
andor
bronchiolar
epitheli
chang
perivascular
peribronchialbronchiolar
alveolar
inflamm
statist
analys
done
use
student
ttest
result
present
mean
standard
error
se
valu
p
consid
signific
previous
demonstr
efficaci
verdinexor
iav
vitro
vivo
mous
model
influenza
infect
verdinexor
target
host
factor
expect
limit
develop
resist
shown
fig
serial
propag
iav
presenc
subvirucid
dose
verdinexor
result
reduct
drug
sensit
vitro
thu
part
preclin
evalu
expand
initi
vivo
find
vivo
efficaci
verdinexor
evalu
comprehens
mice
second
anim
model
influenza
pathogenesi
ie
ferret
support
find
verdinexor
reduc
lung
viru
burden
influenza
virusinfect
mice
amount
infecti
viru
shed
assess
day
pi
fig
mice
receiv
mgkg
verdinexor
day
pi
consider
p
reduc
iav
bronchoalveolar
lavag
fluid
balf
day
pi
compar
iav
observ
oseltamivirtr
mice
sinc
exacerb
inflammatori
respons
associ
sever
influenza
viru
infect
amount
proinflammatori
cytokin
chemokin
balf
also
assess
fig
verdinexortr
mice
significantli
p
lower
balf
compar
mocktreat
mice
level
also
reduc
day
pi
although
statist
signific
compar
oseltamivirtr
mice
mice
treat
verdinexor
also
show
significantli
p
lower
slightli
lower
day
pi
although
differ
statist
signific
interestingli
level
chemokin
rant
elev
verdinexortr
mice
although
signific
increas
inflammatori
cell
recruit
observ
fig
type
bal
cell
determin
flow
cytometri
show
verdinexortr
mice
substanti
lower
immun
cell
infiltr
particular
granulocyt
p
cell
p
nk
cell
p
nkt
cell
p
cell
dendrit
cell
macrophag
fig
repres
flow
cytometri
plot
day
pi
bal
sampl
present
fig
togeth
find
support
therapeut
use
verdinexor
consist
interpret
prior
studi
regard
verdinexor
prophylact
treatment
limit
lung
influenza
viru
replic
pulmonari
inflammatori
respons
infect
mice
ensu
studi
design
evalu
antivir
effect
late
dose
regimen
verdinexor
group
mice
infect
influenza
treat
mgkg
verdinexor
everyotherday
qod
total
dose
start
day
pi
addit
group
mice
receiv
similar
delay
regimen
start
day
pi
lung
viru
titer
evalu
day
pi
fig
delay
verdinexor
treatment
ie
administ
day
pi
later
abl
reduc
lung
viru
titer
compar
better
level
regimen
start
day
pi
p
signific
p
reduct
lung
viru
titer
observ
one
dose
given
day
pi
peak
viru
replic
absenc
treatment
efficaci
late
verdinexor
treatment
assess
improv
surviv
follow
lethal
influenza
viru
challeng
fig
verdinexor
treatment
delay
mortal
still
reduc
group
receiv
mgkg
verdinexor
day
mgkg
day
mgkg
day
pi
p
compar
nontreat
mice
signific
differ
surviv
observ
group
receiv
delay
verdinexor
treatment
control
group
receiv
standard
twicedaili
oseltamivir
regimen
initi
immedi
follow
infect
result
demonstr
verdinexor
efficaci
even
given
later
time
point
postinfect
efficaci
verdinexor
given
alon
combin
oseltamivir
anoth
iav
subtyp
evalu
fig
mice
infect
influenza
either
treat
treat
mgkg
oseltamivir
mgkg
verdinexor
treat
verdinexor
oseltamivir
combin
day
pi
mice
euthan
lung
collect
determin
viru
titer
treatment
group
appreci
lower
lung
viru
titer
compar
nontreat
group
importantli
mice
treat
combin
therapi
mgkg
verdinexor
mgkg
oseltamivir
significantli
lower
titer
compar
receiv
mgkg
verdinexor
p
mgkg
oseltamivir
p
mice
level
viru
assay
detect
limit
result
demonstr
efficaci
verdinexor
multipl
iav
subtyp
augment
antivir
effect
oseltamivir
mous
model
use
extens
studi
host
respons
iav
primarili
lower
cost
reagent
avail
preced
howev
mice
accur
emul
clinic
sign
iav
human
contrast
ferret
model
close
emul
iav
diseas
pathogenesi
furthermor
human
predomin
sialic
acid
sa
found
upper
respiratori
track
ferret
wherea
sa
predomin
mice
pharmacokinet
pk
studi
oral
verdinexor
administr
ferret
conduct
determin
feasibl
investig
vivo
antivir
efficaci
ferret
fig
tabl
studi
show
verdinexor
oral
bioavail
ferret
rapidli
clear
plasma
compar
mice
address
ferret
dose
daili
qd
twice
daili
bid
four
day
total
dose
respect
start
h
prior
infect
nasal
wash
collect
infect
ferret
day
pi
cytolog
evalu
cytokin
express
ferret
sacrif
day
pi
lung
collect
evalu
viru
titer
patholog
ferret
receiv
verdinexor
mgkg
qd
mgkg
qd
mgkg
bid
standard
oseltamivir
treatment
regimen
show
consider
p
reduc
lung
viru
titer
fig
histopatholog
lung
reveal
signific
amelior
influenzaassoci
lung
patholog
inflamm
ferret
receiv
verdinexor
mgkg
qd
p
mgkg
bid
p
fig
howev
limit
reduct
patholog
observ
ferret
receiv
lower
verdinexor
dose
mg
kg
qd
oseltamivir
repres
histopatholog
slide
detail
patholog
report
includ
fig
understand
effect
verdinexor
inflammatori
respons
associ
iav
bronchoalveolar
immun
cell
infiltr
cytokin
express
determin
ferret
nasal
wash
lower
number
infiltr
leukocyt
observ
ferret
receiv
verdinexor
oseltamivir
treatment
day
pi
p
ferret
receiv
verdinexor
mgkg
qd
mgkg
bid
show
signific
p
reduct
day
pi
fig
due
limit
antibodi
avail
ferret
cytokin
detect
qrtpcr
method
employ
detect
cytokin
gene
express
cell
harvest
nasal
wash
fig
ferret
receiv
verdinexor
mgkg
qd
p
mgkg
bid
p
oseltamivir
p
show
reduc
express
nasal
exud
collect
day
pi
ferret
receiv
mgkg
qd
verdinexor
p
oseltamivir
p
also
show
reduc
express
day
pi
except
ferret
receiv
lowest
dose
verdinexor
mgkg
qd
treat
ferret
also
display
trend
toward
reduc
express
day
pi
although
reduct
statist
signific
find
demonstr
verdinexor
efficaci
limit
influenza
viru
infect
associ
patholog
inflamm
second
anim
model
influenza
infect
ie
ferret
togeth
studi
show
verdinexor
potent
inhibitor
iav
replic
vivo
shown
two
anim
model
iav
use
pandem
influenza
viru
strain
furthermor
viru
cultiv
presenc
subefficaci
dose
verdinexor
appear
result
emerg
drug
resist
studi
vivo
late
dose
result
expand
previous
publish
find
verdinexor
antivir
efficaci
mous
model
oseltamivir
administ
within
hour
infect
optim
effect
result
also
demonstr
ad
advantag
verdinexor
treatment
given
late
follow
infect
current
studi
also
show
multifacet
abil
verdinexor
amelior
influenzaassoci
diseas
reduct
lung
viru
titer
inflamm
observ
verdinexortr
mice
ferret
expect
studi
serv
import
step
stone
futur
clinic
evalu
verdinexor
antiinfluenza
indic
human
human
pathogen
virus
also
report
coopt
host
pathway
nuclear
exit
includ
herp
simplex
viru
viru
human
cytomegaloviru
hcmv
sever
acut
respiratori
syndrom
coronaviru
sarscov
thu
like
verdinexor
also
potenti
inhibit
replic
virus
serv
broadspectrum
antivir
verdinexor
test
phase
clinic
trial
healthi
volunt
found
safe
welltoler
clinicaltrialsgov
furthermor
close
relat
sine
compound
selinexor
current
undergo
multipl
separ
phase
ii
studi
human
patient
advanc
relaps
refractori
cancer
clinicaltrialsgov
preliminari
result
studi
demonstr
selinexor
gener
well
toler
good
oral
exposur
evid
anticanc
activ
find
would
also
advoc
verdinexor
safeti
profil
use
human
collect
aliquot
supernat
taken
dilut
infect
new
plate
cell
rest
kept
assess
drug
resist
viru
serial
passag
time
quadrupl
well
conclus
serial
passag
experi
passag
viru
aliquot
thaw
titer
plaqu
assay
assess
potenti
drug
resist
may
aris
serial
passag
subvirucid
dose
verdinexor
stock
viru
wt
virus
use
infect
cell
pretreat
dmso
black
bar
virucid
dose
verdinexor
white
bar
h
moi
hpi
viral
titer
supernat
evalu
use
tcid
method
mean
viru
titer
sem
viru
cultur
presenc
subvirucid
dose
verdinexor
remain
sensit
verdinexor
even
passag
white
bar
panel
c
also
appar
overal
reduct
viral
growth
andor
fit
viru
passag
presenc
verdinexor
black
bar
panel
c
thin
alveolar
septa
empti
alveoli
observ
b
lung
nontreat
influenzainfect
ferret
bronchiol
readili
identifi
due
necrosi
wall
obliter
lumen
inflamm
spill
fill
alveoli
moder
peribronchiolar
perivascular
infiltr
mostli
lymphocyt
present
anim
lung
score
c
lung
infect
ferret
treat
mgkg
qd
verdinexor
bronchiolar
epithelium
partial
necrot
neutrophil
macrophag
partial
fill
lumen
b
mild
peribronchiolar
perivascular
inflamm
present
alveolar
collaps
mild
inflamm
made
parenchyma
appear
consolid
anim
lung
score
lung
infect
ferret
treat
mgkg
qd
verdinexor
bronchiolar
epithelium
mostli
necrot
lumen
fill
neutrophil
macrophag
b
also
found
surround
alveoli
moder
peribronchiolar
perivascular
inflamm
mostli
lymphocyt
present
alveolar
septa
slightli
thicken
anim
lung
score
e
lung
infect
ferret
treat
mgkg
bid
verdinexor
bronchiol
b
line
hyperplast
epithelium
mild
peribronchiolar
perivascular
infiltr
mostli
lymphocyt
alveolar
involv
present
anim
lung
score
f
lung
oseltamivirtr
infect
ferret
bronchiol
line
hyperplast
epithelium
lumen
fill
neutrophil
macrophag
admix
lymphocyt
b
spill
surround
alveoli
mild
peribronchiolar
perivascular
inflamm
mostli
lymphocyt
alveolar
septa
thicken
mild
typeii
cell
hyperplasia
small
number
neutrophil
mononuclear
cell
present
alveoli
anim
lung
score
bar
